Arkolith/Insider Trading/FRTX/Form 4

Marchio Albert N II

CEO and CFO, DirectorFresh Tracks Therapeutics, Inc. (FRTX) · full profile →Form 4 · filed Jan 9, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 28, 2023Disposed to issuer(D)1K$0.91$1K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-24-000949) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML